Skip to content

Machine learning approach to predicting blood glucose level for Type 2 Diabetes Mellitus

Machine learning approach to predicting blood glucose level for Type 2 Diabetes Mellitus

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0003113
Enrollment
300
Registered
2018-08-23
Start date
2018-01-29
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

The Catholic University of Korea, Seoul St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adult aged more than 20 and less than 80 years at screening 2. Subject diagnosis as type 2 Diabetes Mellitus according to 2016 guideline of American Diabetes Association 3. Subject’s HbA1c is under 9% 4. Subject agree to test and entry self-blood glucose on appointed time (6time: before/after 2 hours breakfast, before/ after 2 hours lunch, before/ after 2 hours dinner) and to record diet menus, activities. 5. Subject can received and eat diet of the ‘Dr. KITCHEN’ on week 2 and 3 or during 14days in study period 6. Subject understand the trial explanation, voluntarily decided to participate and signed on informed consent form

Exclusion criteria

Exclusion criteria: 1. Subject has type 1 Diabetes Mellitus or gestational diabetes 2. 20 years or more than from initial diagnosis of diabetes Mellitus 3. Subject take 4 or more Oral hypoglycemic agent or changed the sort of dose diabetic medicine within 3 month (or predict to change during study period) 4. Insulin medicated subject 5. Subject take medicine influence to blood glucose: Corticosteroid or expect to medicate during study period 6. Subject occur myocardial infarction and cerebral infarction within 3 month or has compliance-heart failure 7. Subject has 3 time of upper level AST/ALT or less than 30ml/min GRF, serious renal failure as stage-3 renal disease 8. Subject has currently malignant tumor or history (5 years remission & skin cancer, thyroid cancer, 'carcinoma in situ', investigator desided as completed recovery are acceptable ) 9. Alcoholic or drug dependence 10. Subject has clinical significant psychotic disease not controlled by medication 11. Plan to pregnant or who don’t use of credible contraception [ex: contraceptive mediation or implant, intrauterine contraceptive device, sterilization surgery (vasectomy, tubal legation), barrier method (spermicidal agent and condom, contraceptive vaginal diaphragm, vaginal sponge or use with uterine cervix cap) 12. Subject has clinical significant hypersensitive reaction including allergic disease with trial diet ingredients 13. Subject has gastrointestinal disease affect to absorption of trial diet (Crohn disease, ulcer, acute or chronic pancreatitis etc.) or gastrointestinal operation history (exception: appendectomy or herniotomy, endoscopy submucous resection or endoscopy polypectomy) 14 Continuous drink (more than 21 unit/week = 10g of pure alcohol) during study period 15. Subject will not follow lifestyle to the study protocol 16. Subject inappropriate to the trial as laboratory result and/or other reason by Investigator’s decision 17. Subject participate other medication clinical trial within 3 month from 1st diet date. Investigator can assess subject eligibility with evaluation of medicine half-life

Design outcomes

Primary

MeasureTime frame
pre/postprandial blood glucose

Secondary

MeasureTime frame
diet nutrient information

Countries

Korea, Republic of

Contacts

Public ContactYeoree Yang

The Catholic University of Korea, Seoul St. Mary's Hospital

lambten@gmail.com+82-2-2258-6165

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026